This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OYST Oyster Point Pharma (OYST) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Oyster Point Pharma Stock (NASDAQ:OYST) Get Oyster Point Pharma alerts:Sign Up Key Stats Today's Range$11.17▼$11.1750-Day Range$11.08▼$11.2052-Week Range$3.46▼$19.00Volume330 shsAverage Volume212,171 shsMarket Capitalization$299.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey. Read More Receive OYST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OYST Stock News HeadlinesAviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and InnovationApril 1, 2025 | finance.yahoo.comBillion-dollar real estate bet could spark a biotech revivalMarch 21, 2025 | bizjournals.com$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet. | Weiss Ratings (Ad)Vibrant Wintertime Flower At Oyster Point: PhotoFebruary 20, 2025 | msn.comNext phase of Kilroy's big Oyster Point project sees interest beyond biotechFebruary 11, 2025 | bizjournals.comTed Danson, Kristen Bell and D’Arcy Carden Reunite at “A Man on the Inside ”Premiere 4 Years After “The Good Place ”(Exclusive)November 12, 2024 | msn.comTransmucosal Drug Delivery Pipeline Report 2024 - Stages of Development, Segments, Region and Countries, Regulatory Path and Key CompaniesNovember 12, 2024 | finance.yahoo.comEyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsNovember 7, 2024 | markets.businessinsider.comSee More Headlines OYST Stock Analysis - Frequently Asked Questions How were Oyster Point Pharma's earnings last quarter? Oyster Point Pharma, Inc. (NASDAQ:OYST) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.48. The business earned $17.94 million during the quarter. Oyster Point Pharma had a negative net margin of 901.99% and a negative trailing twelve-month return on equity of 490.33%. When did Oyster Point Pharma IPO? Oyster Point Pharma (OYST) raised $85 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 5,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray acted as the underwriters for the IPO. What other stocks do shareholders of Oyster Point Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oyster Point Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings11/04/2021Today10/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OYST CIK1720725 Webwww.oysterpointrx.com Phone609-382-9032FaxN/AEmployees303Year Founded2015Profitability EPS (Trailing Twelve Months)($6.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$100.66 million Net Margins-901.99% Pretax Margin-901.99% Return on Equity-490.33% Return on Assets-108.29% Debt Debt-to-Equity Ratio8.49 Current Ratio3.35 Quick Ratio3.11 Sales & Book Value Annual Sales$24.54 million Price / Sales12.22 Cash FlowN/A Price / Cash FlowN/A Book Value$3.80 per share Price / Book2.94Miscellaneous Outstanding Shares26,844,000Free Float22,039,000Market Cap$299.85 million OptionableNot Optionable Beta1.31 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:OYST) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oyster Point Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oyster Point Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
